Low-dose fractionated radiation potentiates the effects of cisplatin independent of the hyper-radiation sensitivity in human lung cancer cells

Molecular Cancer Therapeutics

Volumn 10, Issue 2, 2011, Pages 292-302

  Gupta, Seema ^a,b   Koru Sengul, Tulay ^b,c   Arnold, Susanne M ^d   Devi, Gayathri R ^e   Mohiuddin, Mohammed ^f,g   Ahmed, Mansoor M ^a,b  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MIAMI   (United States)

^c UNIVERSITY OF MIAMI   (United States)

^d UNIVERSITY OF KENTUCKY   (United States)

^e DUKE CANCER INSTITUTE   (United States)

^f FOX CHASE CANCER CENTER   (United States)

^g KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE; CLONOGENESIS; COLONY FORMATION; CONTROLLED STUDY; DRUG POTENTIATION; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; HUMAN CELL; LOW ENERGY RADIATION; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; RADIOSENSITIVITY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CELL CYCLE; CELL LINE, TUMOR; CISPLATIN; DOSE FRACTIONATION; DOSE-RESPONSE RELATIONSHIP, RADIATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; RADIATION TOLERANCE;

EID: 79951823580     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-10-0630     Document Type: Article

References (38)

1. Brattstrom D, Bergqvist M, Hesselius P, Wagenius G, Brodin O. Different fraction schedules and combinations with chemotherapy in radiation treatment of non-small cell lung cancer. Anticancer Res 2000;20:2087-90. (Pubitemid 30636188)
2. Santin AD, Hermonat PL, Ravaggi A, Bellone S, Roman J, Pecorelli S, et al. Effects of concurrent cisplatinum administration during radiotherapy vs. radiotherapy alone on the immune function of patients with cancer of the uterine cervix. Int J Radiat Oncol Biol Phys 2000;48:997-1006.
3. Milas L, Mason KA, Liao Z, Ang KK. Chemoradiotherapy: emerging treatment improvement strategies. Head Neck 2003;25: 152-67. (Pubitemid 36133895)
4. Eifel PJ. Chemoradiation for carcinoma of the cervix: advances and opportunities. Radiat Res 2000;154:229-36.
5. Ohno T, Nakano T, Niibe Y, Tsujii H, Oka K. Bax protein expression correlates with radiation-induced apoptosis in radiation therapy for cervical carcinoma. Cancer 1998;83:103-10. (Pubitemid 28299635)
6. Crissman JD, Pajak TF, Zarbo RJ, Marcial VA, Al-Sarraf M. Improved response and survival to combined cisplatin and radiation in non-keratinizing squamous cell carcinomas of the head and neck. An RTOG study of 114 advanced stage tumors. Cancer 1987;59: 1391-7. (Pubitemid 17044991)
7. Schaake-Koning C, Van Den Bogaert W, Dalesio O, Festen J, Hoogenhout J, van Houtte P, et al. Radiosensitization by cytotoxic drugs. The EORTC experience by the Radiotherapy and Lung Cancer Cooperative Groups. Lung Cancer 1994;10Suppl 1:S263-70.
8. Hazuka MB, Crowley JJ, Bunn PA Jr, O'Rourke M, Braun TJ, Livingston RB. Daily low-dose cisplatin plus concurrent high-dose thoracic irradiation in locally advanced unresectable non-small-cell lung cancer: results of a phase II Southwest Oncology Group study. J Clin Oncol 1994;12:1814-20. (Pubitemid 24349382)
9. Geldof AA, Kruit A, Newling DW, Slotman BJ. Synergism between cisplatin and radiotherapy in an in vitro prostate tumor cell line. Anticancer Res 1999;19:505-8. (Pubitemid 29168284)
10. Stewart DJ, Molepo JM, Eapen L, Montpetit VA, Goel R, Wong PT, et al. Cisplatin and radiation in the treatment of tumors of the central nervous system: pharmacological considerations and results of early studies. Int J Radiat Oncol Biol Phys 1994;28:531-42. (Pubitemid 24020543)
11. Blanke C, Ansari R, Mantravadi R, Gonin R, Tokars R, Fisher W, et al. Phase III trial of thoracic irradiation with or without cisplatin for locally advanced unresectable non-small-cell lung cancer: a Hoosier Oncology Group protocol. J Clin Oncol 1995;13:1425-9.
12. Dewit L. Combined treatment of radiation and cisdiamminedichloroplatinum (II): a review of experimental and clinical data. Int J Radiat Oncol Biol Phys 1987;13:403-26. (Pubitemid 17053953)
13. Corde S, Balosso J, Elleaume H, Renier M, Joubert A, Biston MC, et al. Synchrotron photoactivation of cisplatin elicits an extra number of DNA breaks that stimulate RAD51-mediated repair pathways. Cancer Res 2003;63:3221-7. (Pubitemid 36735875)
14. Turchi JJ, Henkels KM, Zhou Y. Cisplatin-DNA adducts inhibit translocation of the Ku subunits of DNA-PK. Nucleic Acids Res 2000;28: 4634-41.
15. Marples B, Lambin P, Skov KA, Joiner MC. Low dose hyper-radiosensitivity and increased radioresistance in mammalian cells. Int J Radiat Biol 1997;71:721-35. (Pubitemid 27306027)
16. Dolling JA, Boreham DR, Brown DL, Mitchel RE, Raaphorst GP. Modulation of radiation-induced strand break repair by cisplatin in mammalian cells. Int J Radiat Biol 1998;74:61-9. (Pubitemid 28320019)
17. Chendil D, Oakes R, Alcock RA, Patel N, Mayhew C, Mohiuddin M, et al. Low dose fractionated radiation enhances the radiosensitization effect of paclitaxel in colorectal tumor cells with mutant p53. Cancer 2000;89:1893-900.
18. Dey S, Spring PM, Arnold S, Valentino J, Chendil D, Regine WF, et al. Low-dose fractionated radiation potentiates the effects of Paclitaxel in wild-type and mutant p53 head and neck tumor cell lines. Clin Cancer Res 2003;9:1557-65. (Pubitemid 36418414)
19. SpringPM, Arnold SM, Shajahan S, Brown B, Dey S, Lele SM, et al. Low dose fractionated radiation potentiates the effects of taxotere in nude mice xenografts of squamous cell carcinoma of head and neck. Cell Cycle 2004;3:479-85. (Pubitemid 40278242)
20. Arnold SM, Regine WF, Ahmed MM, Valentino J, Spring P, Kudrimoti M, et al. Low-dose fractionated radiation as a chemopotentiator of neoadjuvant paclitaxel and carboplatin for locally advanced squamous cell carcinoma of the head and neck: results of a new treatment paradigm. Int J Radiat Oncol Biol Phys 2004;58:1411-7. (Pubitemid 38438301)
21. Joiner MC, Marples B, Lambin P, Short SC, Turesson I. Low-dose hypersensitivity: current status and possible mechanisms. Int J Radiat Oncol Biol Phys 20011;49:379-89.
22. Shareef MM, Brown B, Shajahan S, Sathishkumar S, Arnold SM, Mohiuddin M, et al. Lack of P-glycoprotein expression by low-dose fractionated radiation results from loss of nuclear factor-kappaB and NF-Y activation in oral carcinoma cells. Mol Cancer Res 2008;6: 89-98. (Pubitemid 351378169)
23. Yannelli JR, Hirscowitz E, Wroblewski JM. Growth and functional reactivity of lymphocytes obtained from three anatomic compartments in patients with non-small-cell lung cancer (NSCLC). Cancer Biother Radiopharm 2003;18:735-49. (Pubitemid 37377309)
24. Ahmed MM, Sells SF, Venkatasubbarao K, Fruitwala SM, Muthukkumar S, Harp C, et al. Ionizing radiation-inducible apoptosis in the absence of p53 linked to transcription factor EGR-1. J Biol Chem 1997;272:33056-61. (Pubitemid 28023646)
25. Gupta S, Dwarakanath BS, Muralidhar K, Jain V. Role of apoptosis in photodynamic sensitivity of human tumour cell lines. Indian J Exp Biol 2003;41:33-40. (Pubitemid 36052885)
26. Aird KM, Ding X, Baras A, Wei J, Morse MA, Clay T, et al. Trastuzumab signaling in ErbB2-overexpressing inflammatory breast cancer correlates with X-linked inhibitor of apoptosis protein expression. Mol Cancer Ther 2008;7:38-47.
27. Amantana A, London CA, Iversen PL, Devi GR. X-linked inhibitor of apoptosis protein inhibition induces apoptosis and enhances chemotherapy sensitivity in human prostate cancer cells. Mol Cancer Ther 2004;3:699-707. (Pubitemid 39193751)
28. 2-phase cells. Radiat Res 2004;161: 247-55.
29. Krueger SA, Joiner MC, Weinfeld M, Piasentin E, Marples B. Role of apoptosis in low-dose hyper-radiosensitivity. Radiat Res 2007;167: 260-7. (Pubitemid 351292537)
30. Regine WF, Hanna N, Garofalo MC, Doyle A, Arnold S, Kataria R, et al. Low-dose radiotherapy as a chemopotentiator of gemcitabine in tumors of the pancreas or small bowel: a phase I study exploring a new treatment paradigm. Int J Radiat Oncol Biol Phys 2007;68:172-7. (Pubitemid 46589824)
31. Krueger SA, Collis SJ, Joiner MC, Wilson GD, Marples B. Transition in survival from low-dose hyper-radiosensitivity to increased radioresistance is independent of activation of ATM Ser1981 activity. Int J Radiat Oncol Biol Phys 2007;69:1262-71. (Pubitemid 47625876)
32. Joiner MC, Lambin P, Malaise EP, Robson T, Arrand JE, Skov KA, et al. Hypersensitivity to very-low single radiation doses: its relationship to the adaptive response and induced radioresistance. Mutat Res 1996;358:171-83. (Pubitemid 26384287)
33. Short SC, Woodcock M, Marples B, Joiner MC. Effects of cell cycle phase on low-dose hyper-radiosensitivity. Int J Radiat Biol 2003; 79:99-105. (Pubitemid 36183068)
34. Xu B, Kim ST, Lim DS, Kastan MB. Two molecularly distinct G(2)/M checkpoints are induced by ionizing irradiation. Mol Cell Biol 2002; 22:1049-59.
35. Marples B, Skov KA. Small doses of high-linear energy transfer radiation increase the radioresistance of Chinese hamster V79 cells to subsequent X irradiation. Radiat Res 1996;146:382-7. (Pubitemid 26332770)
36. Caney C, Bulmer JT, Singh G, Lukka H, Rainbow AJ. Pre-exposure of human squamous carcinoma cells to low-doses of gamma-rays leads to an increased resistance to subsequent low-dose cisplatin treatment. Int J Radiat Biol 1999;75:963-72. (Pubitemid 29372054)
37. Edin NJ, Sandvik JA, Olsen DR, Pettersen EO. The elimination of low-dose hyper-radiosensitivity by transfer of irradiated-cell conditioned medium depends on dose rate. Radiat Res 2009;171:22-32.
38. Chandna S, Dwarakanath BS, Khaitan D, Mathew TL, Jain V. Low-dose radiation hypersensitivity in human tumor cell lines: effects of cell-cell contact and nutritional deprivation. Radiat Res 2002;157: 516-25. (Pubitemid 34492558)